Business
Alnylam Launches "Alnylam 2030" Strategy to Drive Next Era of Growth and Patient Impact
CAMBRIDGE, Mass., January 11, 2026--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced its new five-year strategy, "Alnylam 2030," focused on scaling the Company’s operations through achieving leadership in ATTR amyloidosis, driving long-term growth through sustainable innovation, and delivering exceptional financial results with discipline and agility. Alnylam also today reported preliminary* fourth quarter and full year 2025 global net product
About this update from Alnylam Pharmaceuticals, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1552,"height":440,"url":"https://media.zenfs.com/en/business-wire.com/455c56c42750526b34ce3a8cb8181a7e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/j7ijeToOlxZFlgkyjb4UCQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTI3MjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/455c56c42750526b34ce3a8cb8181a7e","width":960,"height":272},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/l7z13a6AOiXhOTLjSn_ocA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD02ODA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/455c56c42750526b34ce3a8cb8181a7e","width":1200,"height":340}},"lazy":false},{"type":"text","content":"− Full Year 2025 Preliminary* Net Product Revenues of $2,987 Million (81% Growth vs. 2024), Driven Primarily by Preliminary* Total TTR Revenues of $2,487 Million (103% Growth vs. 2024) –","length":186,"tagName":"p","attribs":{}},{"type":"text","content":"− Company Provides 2026 Combined Net Product Revenue Guidance of $4,900 Million to $5,300 Million, Driven Primarily by Total TTR Net Product Revenue Guidance of $4,400 Million to $4,700 Million –","length":195,"tagName":"p","attribs":{}},{"type":"text","content":"– 2026 Pipeline Goals Focused on Continued Advancement of Numerous Multi-Billion-Dollar Opportunities –","length":103,"tagName":"p","attribs":{}},{"type":"text","content":"CAMBRIDGE, Mass., January 11, 2026--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced its new five-year strategy, "Alnylam 2030," focused on scaling the Company’s operations through achieving leadership in ATTR amyloidosis, driving long-term growth through sustainable innovation, and delivering exceptional financial results with discipline and agility. Alnylam also today reported preliminary* fourth quarter and full year 2025 global net product revenues for AMVUTTRA, ONPATTRO, GIVLAARI and OXLUMO.","length":580,"tagName":"p"},{"type":"text","content":"New Five-Year Strategy: Alnylam 2030","length":36,"tagName":"p"},{"type":"text","content":"Alnylam 2030 continues the Company’s 15-year heritage of establishing and delivering on ambitious five-year goals, the most recent of which was Alnylam P5x25. Over that time period, Alnylam has either met or ...